



1. AMENDMENTS TO THE SPECIFICATION:

Please replace the paragraph on page 5, beginning at line 18 with the following amended paragraph:


Most preferably the compound is selected from the group consisting of compounds **1** to **6**, **10 to 15, 17, 19, 20, 22, 25, 26, 28, 30, 31, 33 to 37, 39 to 45, 47 to 50, 52 to 58 and 60 to 70** described in provisional PCT international patent application No. PCT/AU02/01427 (which gave rise to United States Patent Appl. Serial No. 10/493,117, published 9/28/06 as 20060217530), including the following compounds:






3

4




5

6




10


11




12




13




14




15




17




19




20




22




25




26




27









28




29




30







41




42




43





44



45





46





57

58




60

61



62

63




64


In a particularly preferred embodiment, the compound is PMX53 (compound 1), compound 33, compound 60 or compound 45 described therein illustrated supra.

Please replace the paragraph on page 12, beginning at line 4 with the following amended paragraph:


Compounds 1-6, 17, 20, 28, 30, 31, 36 and 44 disclosed in International patent application No.PCT/AU98/00490 and compounds 10-12, 14, 15, 25, 33, 35, 40, 45, 48, 52, 58, 60, 66, and 68-70 disclosed for the first time in Australian provisional PCT international patent application No. PCT/AU02/01427 have appreciable antagonist potency ($IC_{50} < 1 \mu M$) against the C5a receptor on human neutrophils. PMX53 (compound 17 of PCT/AU98/00490; also identified as compound 1 in PCT/AU02/01427) and compounds 33, 45 and 60 of PCT/AU02/01427 illustrated infra are most preferred:




J



33



45



60